Vestal Point Discloses 6.0% Stake in Lexeo Therapeutics (LXEO)

Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 3,228,161 shares of Lexeo Therapeutics, Inc. (ticker LXEO), representing 6.0% of the outstanding common stock.

Rhea-AI Filing Summary

Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 3,228,161 shares of Lexeo Therapeutics, Inc. (ticker LXEO), representing 6.0% of the outstanding common stock. The percentage is calculated using an aggregate share count of 53,987,117 shares, reflecting 33,196,997 shares reported as of May 9, 2025, plus 20,790,120 shares issued in a May 27, 2025 private placement. Vestal Point acts as investment manager to a fund and a managed account that hold the shares; Mr. Wilder is the investment manager’s CIO and managing partner and signed the filing. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control.

Positive

• Material disclosure of ownership above the 5% reporting threshold (3,228,161 shares, 6.0%)
• Clear identification of the filing parties: Vestal Point Capital, LP and Ryan Wilder with business addresses and roles
• Calculation basis provided for percent of class using aggregate outstanding shares and noting the May 27, 2025 private placement

Negative

• None.

Insights

Financial Analyst

TL;DR: A 6.0% stake by an investment manager signals a meaningful minority position but the filing asserts passive intent.

The report discloses a position of 3,228,161 shares equal to 6.0% of Lexeo's outstanding common stock based on 53,987,117 shares. As an institutional investor filing under Schedule 13G, Vestal Point is identifying a material economic stake while certifying the holdings are in the ordinary course of business and not for control. This is a material ownership disclosure because it exceeds the 5% threshold that requires public reporting; however, the filing does not indicate activist intentions, additional transactions, or planned changes to board or capital structure.

Corporate Governance Expert

TL;DR: Ownership exceeds the 5% reporting threshold but the certifying language denotes a passive, non-control purpose.

The filing names Vestal Point Capital, LP as investment manager and Ryan Wilder as the individual associated with the position. The Schedule 13G classification and the signed certification state the shares are held in the ordinary course of business and not to influence control, which aligns with passive investor treatment under the Exchange Act. From a governance perspective, the disclosure provides transparency on significant ownership and the responsible signatory but does not signal any governance actions or nominations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Lexeo Therapeutics (LXEO) shares does Vestal Point Capital report owning?

The filing reports beneficial ownership of 3,228,161 shares of Lexeo common stock.

What percentage of LXEO does the reported stake represent?

The reported position represents 6.0% of Lexeo's outstanding common stock based on 53,987,117 shares.

Who filed the Schedule 13G for LXEO and who signed it?

The Schedule 13G was filed by Vestal Point Capital, LP and Ryan Wilder; both signatures were provided by Mr. Wilder.

Does the filing state the shares were acquired to influence control of Lexeo (LXEO)?

No. The certification states the securities were acquired and are held in the ordinary course of business and not to influence control.

What share count did the filing use to calculate the 6.0% ownership?

The percentage is based on an aggregate of 53,987,117 shares, combining prior outstanding shares and 20,790,120 shares issued on May 27, 2025 in a private placement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 03:51 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lexeo Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

52886X107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Vestal Point Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,228,161.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,228,161.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,228,161.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Ryan Wilder

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,228,161.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,228,161.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,228,161.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lexeo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 345 Park Avenue South, Floor 6, New York, NY 10010
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Lexeo Therapeutics, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
(c)	Citizenship: The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 52886X107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 53,987,117 shares of Common Stock outstanding, which is the sum of: (i) 33,196,997 shares of Common Stock outstanding as of May 9, 2025, as reported in Amendment No. 1 to the Company's Quarterly Report on Form 10-Q/A for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025; and (ii) 20,790,120 shares of Common Stock issued by the Company on May 27, 2025, in connection with a private placement, as described in the Current Report on Form 8-K filed with the SEC on May 27, 2025.
(b)	Percent of class: 6.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vestal Point Capital, LP

Signature:	/s/ Ryan Wilder
Name/Title:	By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Date:	08/14/2025

Ryan Wilder

Signature:	/s/ Ryan Wilder
Name/Title:	Ryan Wilder, Individually
Date:	08/14/2025

Exhibit Information

Exhibit 99.1: Joint Filing Agreement